Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change $ Change
grade F $3.88 -1.02% -0.04
AGEN closed down 1.02 percent on Friday, March 24, 2017, on 60 percent of normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical AGEN trend table...

Date Alert Name Type % Chg
Mar 24 Narrow Range Bar Range Contraction 0.00%
Mar 23 Stochastic Reached Oversold Other -1.02%
Mar 22 Doji - Bullish? Reversal 0.26%
Mar 21 Fell Below 50 DMA Bearish 0.78%
Mar 21 Expansion Pivot Sell Setup Bearish Swing Setup 0.78%
Mar 20 Crossed Above 50 DMA Bullish -5.37%
Mar 20 Spinning Top Other -5.37%
Mar 20 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.37%
Mar 17 Fell Below 50 DMA Bearish -3.96%
Mar 16 NR7 Range Contraction -6.73%

Older signals for AGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer’s disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company’s products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Is AGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.49
52 Week Low 2.97
Average Volume 1,235,277
200-Day Moving Average 4.9198
50-Day Moving Average 4.0292
20-Day Moving Average 4.0615
10-Day Moving Average 4.02
Average True Range 0.2034
ADX 13.57
+DI 16.67
-DI: 24.47
Chandelier Exit (Long, 3 ATRs) 3.7498
Chandelier Exit (Short, 3 ATRs) 4.3602
Upper Bollinger Band 4.3221
Lower Bollinger Band 3.8009
Percent B (%b) 0.15
Bandwidth 0.128327